Dawson James Reiterates Buy Rating on Sorrento Therapeutics (SRNE) on FDA Clearance for Phase 2 of Abivertinib in COVID-19

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/11/2026

1. ORCL
2. SPY
3. NAVN
4. HUMA
5. CHWY
6. USO
7. SPCX
8. cASY
9. PCT
10. INTC

Go back to Dawson James Reiterates Buy Rating on Sorrento Therapeutics (SRNE) on FDA Clearance for Phase 2 of Abivertinib in COVID-19

FDA clears Abivertinib for Phase 2 safety and efficacy study in hospitalized patients with moderate to severe COVID-19

July 20, 2020 9:00 AM EDT

SAN DIEGO, July 20, 2020 /PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today received clearance from the FDA to initiate a Phase 2 trial of Abivertinib in patients with COVID-19 who have moderate to severe pulmonary symptoms.

Abivertinib is a novel small molecule tyrosine kinase inhibitor (TKI) that selectively... More